Search research articles
Contact Us
Filters
Showing results (181-190 of 489) with videos related to
Page
of 49
Sort By:
Biometrics
|
April 21, 2001
Closed testing procedures for group sequential clinical trials with multiple endpoints
D I Tang, N L Geller
Biometrics
|
April 5, 2019
Discussion of "A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III" by Andrew G. Chapple and Peter F. Thall
Eric S Leifer, Nancy L Geller
The Journal of Biological Chemistry
|
August 10, 1982
Rat liver Cu,Zn-superoxide dismutase. Subcellular location in lysosomes
B L Geller, D R Winge
Psychiatric Services (Washington, D.C.)
|
July 4, 2006
The recovery model and seclusion and restraint
Kris A McLoughlin, Jeffrey L Geller
Hospital & Community Psychiatry
|
January 1, 1985
Competency to stand trial: neuroleptic medication and demeanor in court
J L Geller, P S Appelbaum
Biometrics
|
June 1, 1991
On the choice of times for data analysis in group sequential clinical trials
Z H Li, N L Geller
Psychiatric Services (Washington, D.C.)
|
August 2, 2014
Personal accounts: recovery is resilience in the face of symptoms
Richard J Stewart, Jeffrey L Geller
Sovetskaia Meditsina
|
January 1, 1987
[Extraintestinal complications of nonspecific ulcerative colitis and Crohn's disease]
L I Geller, A L Geller
Sovetskaia Meditsina
|
January 1, 1987
[Effect of pentagastrin on gastric secretion and blood flow in the gastric mucosa in chronic gastritis]
L I Geller, A L Geller
Antimicrobial Agents and Chemotherapy
|
December 24, 2004
Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli
Jesse Deere, Pat Iversen, Bruce L Geller
Page
of 49
Search research articles
Search
Showing results (181-190 of 489) with videos related to
Sort By:
Page
of 49
Biometrics
|
April 21, 2001
Closed testing procedures for group sequential clinical trials with multiple endpoints
D I Tang, N L Geller
Biometrics
|
April 5, 2019
Discussion of "A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III" by Andrew G. Chapple and Peter F. Thall
Eric S Leifer, Nancy L Geller
The Journal of Biological Chemistry
|
August 10, 1982
Rat liver Cu,Zn-superoxide dismutase. Subcellular location in lysosomes
B L Geller, D R Winge
Psychiatric Services (Washington, D.C.)
|
July 4, 2006
The recovery model and seclusion and restraint
Kris A McLoughlin, Jeffrey L Geller
Hospital & Community Psychiatry
|
January 1, 1985
Competency to stand trial: neuroleptic medication and demeanor in court
J L Geller, P S Appelbaum
Biometrics
|
June 1, 1991
On the choice of times for data analysis in group sequential clinical trials
Z H Li, N L Geller
Psychiatric Services (Washington, D.C.)
|
August 2, 2014
Personal accounts: recovery is resilience in the face of symptoms
Richard J Stewart, Jeffrey L Geller
Sovetskaia Meditsina
|
January 1, 1987
[Extraintestinal complications of nonspecific ulcerative colitis and Crohn's disease]
L I Geller, A L Geller
Sovetskaia Meditsina
|
January 1, 1987
[Effect of pentagastrin on gastric secretion and blood flow in the gastric mucosa in chronic gastritis]
L I Geller, A L Geller
Antimicrobial Agents and Chemotherapy
|
December 24, 2004
Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli
Jesse Deere, Pat Iversen, Bruce L Geller
Page
of 49